purevax felv
boehringer ingelheim vetmedica gmbh - virus mačje leukemije rekombinantnog kanarinaca (vcp97) - imunomodulatori za mačke, - mačke - aktivna imunizacija mačaka starijih od 8 tjedana protiv mačje leukemije radi sprečavanja perzistirajuće viremije i kliničkih znakova povezane bolesti. otkrivanje imuniteta pokazalo se 2 tjedna nakon primarnog cijepljenja. trajanje imuniteta je jedna godina nakon posljednjeg cijepljenja.
purevax rc
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.
purevax rcp
boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.
purevax rcp felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
purevax rcpch
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. pokusi imuniteta pokazani su tjedan dana nakon primarnog cijepljenja za rhinotracheitis, kalicivirus, chlamydophila felis i panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
purevax rcpch felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
coliprotec f4
prevtec microbia gmbh - žive patogene escherichia coli o8: k87 - immunologicals for suidae, live bacterial vaccines, pig - svinje - za aktivne imunizacije svinja protiv энтеротоксигенных Ф4-pozitivne e. coli je:smanjiti učestalost umjerene do teške nakon odbića e. coli proljev (ФРД) u svinje;smanjenje kolonizacije u tankom i fekalne prolijevanja энтеротоксигенных Ф4-pozitivne e. coli iz zaraženih svinja.
ecoporc shiga
ceva santé animale - genetski modificirani рекомбинантный Шига-toksin-antigen 2e - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) - svinje - aktivna imunizacija praščića od dobi od četiri dana, kako bi se smanjila smrtnost i klinički znakovi bolesti edema uzrokovanih shiga toksinom 2e koji su proizveli escherichia coli (stec). početak imuniteta: 21 dan nakon cijepljenja. trajanje imuniteta: 105 dana nakon cijepljenja.
eryseng
laboratorios hipra, s.a. - erysipelothrix rhusiopathiae, soj r32e11 (inaktiviran) - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - svinje - za aktivne imunizacije mužjaci i ženke svinja za smanjenje kliničkih manifestacija (oštećenje kože i groznica) svinjske vrbanca, uzrokovane Эризипелотриксов rhusiopathiae, серотип серотип 1 i 2.
eryseng parvo
laboratorios hipra, s.a. - svinjski parvovirus, soj nadl-2 i erysipelothrix rhusiopathiae, soj r32e11 (inaktiviran) - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svinje - za aktivnu imunizaciju ženke svinje za zaštitu potomaka protiv transplacentalne infekcije uzrokovane svinjskim parvovirusom. za aktivne imunizacije mužjaci i ženke svinja za smanjenje kliničkih manifestacija (oštećenje kože i groznica) svinjske vrbanca, uzrokovane Эризипелотриксов rhusiopathiae, серотип серотип 1 i 2.